House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Haematology

Blood transfusion

NICE · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG24 provides general transfusion principles for adults, young people and children from one year of age, with updated perioperative tranexamic-acid recommendations. It combines prevention of avoidable transfusion, component-specific thresholds, small initial doses with reassessment, and recognition of transfusion reactions.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Treat iron deficiency and use surgical blood-conservation measures

  • Offer oral iron before and after surgery for iron-deficiency anaemia. Consider IV iron when oral treatment cannot be tolerated, absorbed or adhered to, when functional iron deficiency is diagnosed, or when the interval to surgery is too short for oral treatment to work. [1]
  • Do not use erythropoietin routinely to reduce surgical transfusion needs. Exceptions are anaemia meeting transfusion criteria when blood is declined, or absence of compatible blood because of red-cell antibodies. [1]
  • Offer tranexamic acid to adults having operating-theatre surgery when there is bleeding risk and the procedure breaches skin or mucosa. Outside theatre, offer it when expected blood loss exceeds 500 ml; typically administer 1 g by slow IV injection just before surgery. [1]
  • For children aged 1–15, consider tranexamic acid in theatre when surgery breaches skin or mucosa and carries bleeding risk, or outside theatre when expected loss exceeds 10% of blood volume. Typically give 15 mg/kg, maximum 1 g, slowly IV just before surgery. [1]
  • Before additional tranexamic-acid doses, weigh prolonged surgery or blood-loss benefit against risk, including accumulation with renal impairment. Put safeguards in place against accidental intrathecal or epidural administration. [1]
  • Consider intraoperative cell salvage together with tranexamic acid when very high blood loss is expected, such as complex cardiac, vascular, pelvic or scoliosis surgery. Do not routinely use cell salvage without tranexamic acid. [1]

Use restrictive thresholds only in the appropriate population

  • For people needing red cells without major haemorrhage, acute coronary syndrome or regular transfusion for chronic anaemia, use a restrictive approach. Consider a haemoglobin threshold of 70 g/litre and a post-transfusion target of 70–90 g/litre. [1]
  • In acute coronary syndrome, consider a red-cell threshold of 80 g/litre and a post-transfusion target of 80–100 g/litre. Set individualized thresholds and targets for people receiving regular transfusions for chronic anaemia. [1]
  • For adults without active bleeding, consider one red-cell unit at a time; use weight-equivalent volumes in children and low-weight adults. After each dose, reassess clinically and recheck haemoglobin before deciding whether more is needed. [1]

Match platelet thresholds to bleeding and procedure risk

  • Offer platelets for thrombocytopenia with clinically significant WHO grade 2 bleeding and a count below 30×10^9/litre. Use higher thresholds, up to 100×10^9/litre, for severe WHO grade 3–4 bleeding or critical-site bleeding such as the CNS or eyes. [1]
  • When there is no bleeding or planned invasive procedure, offer prophylactic platelets below 10×10^9/litre, except in chronic marrow failure, autoimmune thrombocytopenia, HIT or TTP. Routine prophylactic platelets are not recommended for those excluded conditions. [1]
  • For invasive procedures or surgery, consider platelet transfusion to raise the count above 50×10^9/litre. Consider 50–75×10^9/litre in high-risk cases according to procedure, cause, falling count and other haemostatic abnormalities; for critical-site surgery, consider above 100×10^9/litre. [1]
  • Do not give prophylactic platelets for low-bleeding-risk procedures such as adult central venous cannulation or marrow aspiration and trephine biopsy. Do not routinely give more than one platelet dose; reassess clinically and check the count after each transfusion before further dosing. [1]

Use plasma and cryoprecipitate for their stated indications

  • For clinically significant bleeding without major haemorrhage, consider FFP only with abnormal coagulation tests, such as PT or aPTT ratio above 1.5. Consider prophylactic FFP for abnormal coagulation before procedures carrying clinically significant bleeding risk. [1]
  • Do not give FFP solely to correct abnormal coagulation in a non-bleeding patient unless a bleeding-risk procedure is planned, or for vitamin-K-antagonist reversal. After FFP, reassess clinically and repeat coagulation testing to decide whether more is needed. [1]
  • Without major haemorrhage, consider cryoprecipitate for clinically significant bleeding with fibrinogen below 1.5 g/litre. Before an invasive procedure or surgery carrying significant bleeding risk, consider prophylaxis if fibrinogen is below 1.0 g/litre. [1]
  • Do not use cryoprecipitate to correct fibrinogen when there is neither bleeding nor a planned procedure with significant bleeding risk. Use 2 pools in adults, or 5–10 ml/kg in children up to 2 pools, then reassess clinically and repeat fibrinogen measurement. [1]

Recognize urgent reversal and monitor every transfusion

  • Offer immediate PCC for emergency warfarin reversal in severe bleeding or head injury with suspected intracerebral haemorrhage. Consider it for emergency surgery according to anticoagulation level and bleeding risk; monitor INR to confirm reversal and consider further PCC if required. [1]
  • Monitor clinical condition and vital signs before, during and after transfusion in a setting with staff able to recognize and manage acute reactions. Consider electronic patient identification to improve transfusion safety. [1]
  • Provide verbal and written information about the reason, risks, benefits, process and alternatives, and document discussions. Give the person and primary-care clinician a written record of transfusions, indications and adverse events, including the source’s blood-donation eligibility advice. [1]

Limitations and use

  • The guideline excludes pregnancy and labour, infants under one year, haemoglobinopathies, trauma and massive haemorrhage, and several other specialist transfusion settings. Its general thresholds must not substitute for those pathways. It does not provide compatibility-testing procedures, a complete acute-reaction treatment protocol or a complete anticoagulant-reversal regimen. Many child recommendations extrapolate adult evidence.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Blood transfusion

    Guideline recommendation text consulted

Clinical guideline

Publication details

Issuing organisation
NICE
First published
18 November 2015
Publisher’s latest update
26 February 2026
Resource type
Clinical guideline · House clinical summary
Source setting
United Kingdom

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Treat iron deficiency and use surgical blood-conservation measures
  • Use restrictive thresholds only in the appropriate population
  • Match platelet thresholds to bleeding and procedure risk
  • Use plasma and cryoprecipitate for their stated indications
  • Recognize urgent reversal and monitor every transfusion
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House